HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dingell Challenged To Document Reasons For Supplement Safety Doubts

This article was originally published in The Tan Sheet

Executive Summary

The president of Jarrow Formulas has formally challenged House Energy and Commerce Committee Chairman John Dingell, D-Mich., to back up claims that dietary supplements "are killing people," and says he does not expect Dingell will act on plans to conduct hearings on the Dietary Supplement Health and Education Act

You may also be interested in...



Jarrow Formulas Founder Forms “More Creative” Supplement Trade Group

A dietary supplement trade group founded by Jarrow Rogovin plans to aggressively protect the industry’s interests, including filing lawsuits and Freedom of Information Act requests.

Hearings May Probe FDA Enforcement Of Supplement “Bad Actors” – Pallone

Possible House Energy and Commerce Health Subcommittee hearings would likely focus on what is needed to improve FDA enforcement against "bad actors" for violations of the Dietary Supplement Health and Education Act of 1994, according to Rep. Frank Pallone, D-N.J

Democrats Expected To Put Supplement, Drug Regulation Under Microscope

Increased scrutiny of issues including the safety of dietary supplements and phenylephrine efficacy is likely as senior Democrats move into leadership roles on Congressional committees following the 2006 midterm elections

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel